Ipidacrine-d₁₀  (Synonyms: NIK-247-d₁₀ free base)

Ipidacrine-d₉ (NIK-247-d₉ (free base)) is the deuterium labeled Ipidacrine (HY-W027553). Ipidacrine is orally active and brain-penetrant AChE and BuChE inhibitors with IC₅₀ values of 1 μM and 1.9 μM, respectively, which is also a partial agonist of M2-cholinergic receptors and a reversible cholinesterase inhibitor. Ipidacrine has a stimulating effect on neuromuscular transmission and excitation along the nerve fibres with a moderately anti-pain effect. Ipidacrine is an aminopyridines and is structurally similar to Tacrine (HY-111338). Ipidacrine is effective in various amnesia models, improves erectile function and inhibits K+ and Na+-channels in the neuronal membrane in diabetic rats. Ipidacrine is promising for research of Alzheimer’s disease, ischaemic stroke, idiopathic neuropathy of the facial nerve, diabetes mellitus-induced erectile dysfunction and other deficits in central or peripheral cholinergic deseases^{[1][2][3][4][5]}.

氢、碳和其他元素的稳定重同位素已被掺入药物分子中，主要用作药物开发过程中定量的示踪剂。氘化因其可能影响药物的药代动力学和代谢特征而受到关注。

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

198.33

C₁₂H₆D₁₀N₂

62732-44-9

Room temperature in continental US; may vary elsewhere.

Please store the product under the recommended conditions in the Certificate of Analysis.

• [1]. Kojima J, et al. Ipidacrine (NIK-247): A Review of Multiple Mechanisms as an Antidementia Agent[J]. CNS Drug Reviews, 1998, 4(3): 247-259.

  [2]. Pulatov S S. Efficacy of ipidacrine in the recovery period of ischaemic stroke[J]. World Bulletin of Public Health, 2022, 7: 28-32.

  [3]. Bykov V, et al. Ipidacrine (Axamon), A Reversible Cholinesterase Inhibitor, Improves Erectile Function in Male Rats With Diabetes Mellitus-Induced Erectile Dysfunction[J]. Sex Med. 2022 Feb;10(1):100477.  [Content Brief]

  [4]. Zinovyeva O E, et al. Ipidacrine efficacy in diabetic polyneuropathy complex treatment: A review[J]. Consilium Medicum, 2022, 24(2): 123-127.

  [5]. Samartsev I N, et al. The efficacy and safety of ipidacrine in patients with idiopathic neuropathy of the facial nerve (PELICAN study)[J]. Neurology, Neuropsychiatry, Psychosomatics, 2022, 14(1): 60-68.